M.D. Anderson Cancer Center: Leukemia, Myelomonocytic, Chronic trials

The registry lists 42 Leukemia, Myelomonocytic, Chronic studies with M.D. Anderson Cancer Center as lead sponsor. 10 are open to participants now and 14 have results posted.

Phase 1 22Phase 2 34Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
• A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.RecruitingNCT06566742Phase 2
• Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaRecruitingNCT04239157Phase 2
• Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
• CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecruitingNCT03896269Phase 1
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeRecruitingNCT03383575Phase 2
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedNCT03047993Phase 1/2Results posted
• Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantCompletedNCT02684162Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01892371Phase 1/2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01664897Phase 2Results posted
• Oral Clofarabine Study in Patients With Myelodysplastic SyndromeCompletedNCT00299156Phase 2Results posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureTerminatedNCT00113321Phase 2Results posted
• Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)CompletedNCT00067808Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmWithdrawnNCT06597734Phase 2
• Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnNCT06085638Phase 1/2
• Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic SyndromesActive, not recruitingNCT05038592Phase 1/2
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04734990Phase 1/2
• Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaActive, not recruitingNCT04655755Phase 1/2
• Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaTerminatedNCT04550442Phase 1/2
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
• Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic SyndromeTerminatedNCT04160052Phase 1/2
• Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02649764Phase 1
• Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesActive, not recruitingNCT02530034Phase 1
• Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)TerminatedNCT00074750Phase 1
• Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid MalignanciesCompletedNCT00038051Phase 1
• Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedNCT00002833Phase 2